Mostly Markets
Subscribe
Markets
S&P 500 ▼ 1.82%Nasdaq ▼ 2.86%Dow ▼ 1.09%Russell 2000 ▼ 1.66%10-year 4.93%Oil ▲ 0.93%Gold ▼ 3.63%Bitcoin ▲ 1.13%
Newest story
Stocks/Health Care/Health Care Equipment

Zimmer BiometZBH

Health Care Equipment · Warsaw, Indiana · In the S&P 500
Solid businessCheaper than peers
$94.52−3.03%After hours: $95.00 (+0.51%)At the close, 30 Oct · Prices from CNBC, may be delayed
▼ 5.2% over 1 year
Zimmer Biomet over 1 yearDaily close, $, to 30 Oct 2026
$80$90$100Nov2026MarMayJulSep$94.52$80$90$100NovMarJul$94.52
Source: Nasdaq daily closes
Market value$18.03B
Price to earnings23.0x
Forward P/E10.8x
Dividend yield1.02%
Year to date+5.1%
One year−5.2%
Next earningsWed 4 Nov, before the open
SectorHealth Care
52-week range (closes)
$79.58$103.18

The latest on Zimmer Biomet

Our stories first, then the headlines that could move it, newest first.

We haven't written about Zimmer Biomet yet. Follow it, and its first story will show under My stocks.

Quality and valuation

How Zimmer Biomet compares with other health care stocks. A description, not a recommendation.

Zimmer Biomet and 7 health care equipment peers. Across: valuation (P/E) against the sector. Up: business quality against the sector. Hover or tap a logo for its numbers.

Business quality: about averageValuation: cheaper than most

An average business among health care companies, priced below most of them.

Zimmer Biomet trades at 10.8 times the next 12 months of expected earnings, against a median of 19.1x for the 65 health care stocks we cover. The quality score blends where it ranks on revenue growth, gross margin, operating margin and free-cash-flow margin (net margin for banks and insurers) over the last 12 months, from SEC filings.

  • Revenue grew faster than the sector median: +8.6% vs +7.8%
  • Keeps more of each sale (gross margin): 69.9% vs 65.3%
  • More profitable (operating margin): 14.2% vs 13.3%
  • Turns more of its sales into cash: 17.9% vs 15.9%
ZBH trades at 10.8x forward earnings, below the sector medianForward p/e, Health Care Equipment peers
ZBH10.8xBSX13.8xBDX15.0xMDT16.1xSYK18.4xABT18.6xEW29.3xISRG37.5xSector median 19.1xZBH10.8xBSX13.8xBDX15.0xMDT16.1xSYK18.4xABT18.6xEW29.3xISRG37.5xSector median 19.1x
Source: CNBC quotes; Mostly Markets
At 23.0x earnings, ZBH is pricier than its average since Aug 2024Price over the last 12 months of reported (GAAP) diluted EPS
P/EUsual range (±1 s.d.)
20x25xAverage 22.8x2025202623.0x20x25xAverage 22.8x2025202623.0x
Source: Nasdaq prices; SEC filings

Financials

From Zimmer Biomet's SEC filings, through the quarter ending 30 Jun 2026. Hover or tap a bar for its value.

Revenue grew 4.8% from a year earlierQuarterly revenue, $bn, latest Q2 ’26
$0bn$1bn$2bnQ3 ’24Q1 ’25Q3 ’25$2.2bnQ2 ’26$0bn$1bn$2bnQ3 ’24Q1 ’25Q3 ’25$2.2bnQ2 ’26
Source: SEC filings
Growth slowed to +4.8% last quarterRevenue growth, year on year, %
0%5%10%Q3 ’24Q1 ’25Q3 ’254.8%Q2 ’260%5%10%Q3 ’24Q1 ’25Q3 ’254.8%Q2 ’26
Source: SEC filings
Operating margin was 15.0% last quarterOperating income as a share of revenue, %
0%5%10%15%Q3 ’24Q1 ’25Q3 ’2515.0%Q2 ’260%10%Q3 ’24Q1 ’25Q3 ’2515.0%Q2 ’26
Source: SEC filings
Free cash flow was $1.5 billion over 12 monthsQuarterly free cash flow (operating cash flow minus capex), $m
$0m$200m$400mQ3 ’24Q1 ’25Q3 ’25$394mQ2 ’26$0m$200m$400mQ3 ’24Q1 ’25Q3 ’25$394mQ2 ’26
Source: SEC filings
Last 12 monthsZBHSector median
Revenue growth+8.6%+7.8%
Gross margin69.9%65.3%
Operating margin14.2%13.3%
Free cash flow margin17.9%15.9%
Price to earnings23.0x30.2x

Similar companies

Health Care Equipment, by market value.

CompanyPriceTodayYTDValue
ABTAbbott Laboratories$106.20+1.56%−15.2%$184B
ISRGIntuitive Surgical$432.01−3.73%−23.7%$150B
MDTMedtronic$96.54−0.59%+0.5%$123B
SYKStryker$291.86−6.38%−17.0%$112B
BSXBoston Scientific$41.98−1.66%−56.0%$60.84B
BDXBecton Dickinson$197.88−0.23%+27.4%$53.90B
EWEdwards Lifesciences$92.01−2.57%+7.9%$53.03B
IDXXIdexx Laboratories$551.21−4.30%−18.5%$43.42B